366 related articles for article (PubMed ID: 16292454)
21. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.
Paul C; Coustou D; Lahfa M; Bulai-Livideanu C; Doss N; Mokthar I; Turki H; Nouira R; Fazaa B; Ben Osman A; Zourabichvili O; Cazeau C; Coubetergues H; Picot S; Bienvenu AL; Voisard JJ
Dermatology; 2013; 227(2):157-64. PubMed ID: 24051622
[TBL] [Abstract][Full Text] [Related]
22. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
Gupta AK; Fleckman P; Baran R
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S70-80. PubMed ID: 11051136
[TBL] [Abstract][Full Text] [Related]
23. Treatment costs of three nail lacquers used in onychomycosis.
Marty JP; Lambert J; Jäckel A; Adjadj L
J Dermatolog Treat; 2005; 16(5-6):299-307. PubMed ID: 16428149
[TBL] [Abstract][Full Text] [Related]
24. The use of topical therapies to treat onychomycosis.
Gupta AK; Ryder JE; Baran R
Dermatol Clin; 2003 Jul; 21(3):481-9. PubMed ID: 12956200
[TBL] [Abstract][Full Text] [Related]
25. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement.
Baran R; Sigurgeirsson B; de Berker D; Kaufmann R; Lecha M; Faergemann J; Kerrouche N; Sidou F
Br J Dermatol; 2007 Jul; 157(1):149-57. PubMed ID: 17553051
[TBL] [Abstract][Full Text] [Related]
26. Development of ciclopirox nail lacquer with enhanced permeation and retention.
Thapa RK; Choi JY; Go TG; Kang MH; Han SD; Jun JH; Son MW; Yong CS; Kim JO
Arch Pharm Res; 2016 Jul; 39(7):953-9. PubMed ID: 27306785
[TBL] [Abstract][Full Text] [Related]
27. Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes.
Schalka S; Nunes S; Gomes Neto A
An Bras Dermatol; 2012; 87(1):19-25. PubMed ID: 22481647
[TBL] [Abstract][Full Text] [Related]
28. Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers.
Hafeez F; Hui X; Selner M; Rosenthal B; Maibach H
Drug Dev Ind Pharm; 2014 Jun; 40(6):838-44. PubMed ID: 23600655
[TBL] [Abstract][Full Text] [Related]
29. A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers.
Sidou F; Soto P
Int J Tissue React; 2004; 26(1-2):17-24. PubMed ID: 15573688
[TBL] [Abstract][Full Text] [Related]
30. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
Bohn M; Kraemer KT
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S57-69. PubMed ID: 11051135
[TBL] [Abstract][Full Text] [Related]
31. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study.
Gupta AK;
J Drugs Dermatol; 2005; 4(4):481-5. PubMed ID: 16004022
[TBL] [Abstract][Full Text] [Related]
32. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails.
Casciano J; Amaya K; Doyle J; Arikian S; Shear N; Haspel M; Kahler K
Manag Care; 2003 Mar; 12(3):47-54. PubMed ID: 12685377
[TBL] [Abstract][Full Text] [Related]
33. Establishment of a novel model of onychomycosis in rabbits for evaluation of antifungal agents.
Shimamura T; Kubota N; Nagasaka S; Suzuki T; Mukai H; Shibuya K
Antimicrob Agents Chemother; 2011 Jul; 55(7):3150-5. PubMed ID: 21555762
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of a new medicated nail hydrolacquer in the treatment of adults with toenail onychomycosis: A randomised clinical trial.
Zalacain-Vicuña AJ; Nieto C; Picas J; Martínez H; Bermejo R; Corrales A; Campos FF; Igea SA; Otero-Espinar FJ; Briones VG
Mycoses; 2023 Jul; 66(7):566-575. PubMed ID: 36336989
[TBL] [Abstract][Full Text] [Related]
35. Double-blind clinical trial for evaluating the effectiveness and tolerability of Ageratina pichinchensis extract on patients with mild to moderate onychomycosis. A comparative study with ciclopirox.
Romero-Cerecero O; Zamilpa A; Jiménez-Ferrer JE; Rojas-Bribiesca G; Román-Ramos R; Tortoriello J
Planta Med; 2008 Oct; 74(12):1430-5. PubMed ID: 18671197
[TBL] [Abstract][Full Text] [Related]
36. A clinical and laboratory study of ciclopirox olamine (8% Batrafen) in the treatment of onychomycosis.
Yu B; Zhou G; Wang B; Ben Y; Yan H; Shao Y; Wang B
Chin Med Sci J; 1991 Sep; 6(3):166-8. PubMed ID: 1838936
[TBL] [Abstract][Full Text] [Related]
37. Onychomycosis due to Neoscytalidium treated with oral terbinafine, ciclopirox nail lacquer and nail abrasion: a pilot study of 25 patients.
Cursi ÍB; Silva RT; Succi IB; Bernardes-Engemann AR; Orofino-Costa R
Mycopathologia; 2013 Feb; 175(1-2):75-82. PubMed ID: 22976905
[TBL] [Abstract][Full Text] [Related]
38. Onychomycosis and diabetes.
Cathcart S; Cantrell W; Elewski Be
J Eur Acad Dermatol Venereol; 2009 Oct; 23(10):1119-22. PubMed ID: 19309423
[TBL] [Abstract][Full Text] [Related]
39. Hydroxypropyl chitosan nail lacquer of ciclopirox-PLGA nanocapsules for augmented in vitro nail plate absorption and onychomycosis treatment.
Gaballah EY; Borg TM; Mohamed EA
Drug Deliv; 2022 Dec; 29(1):3304-3316. PubMed ID: 36372978
[TBL] [Abstract][Full Text] [Related]
40. Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy.
Friedlander SF; Chan YC; Chan YH; Eichenfield LF
Pediatr Dermatol; 2013; 30(3):316-22. PubMed ID: 23278851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
